A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Br J Dermatol. 2021 06; 184(6):1047-1058.BJ

Abstract

BACKGROUND

Significantly more patients with moderate-to-severe plaque psoriasis treated with the interleukin (IL)-17A inhibitor ixekizumab vs. the IL-23p19 inhibitor guselkumab in the IXORA-R head-to-head trial achieved 100% improvement in Psoriasis Area and Severity Index (PASI 100) at week 12.

OBJECTIVES

To compare skin and nail clearance and patient-reported outcomes for ixekizumab vs. guselkumab, up to week 24.

METHODS

IXORA-R enrolled adults with moderate-to-severe plaque psoriasis, defined as static Physician's Global Assessment ≥ 3, PASI ≥ 12 and involved body surface area ≥ 10%. Statistical comparisons were performed using the Cochran-Mantel-Haenszel test stratified by pooled site. Time-to-first-event comparisons were performed using Kaplan-Meier analysis, and P-values were generated using adjusted log-rank tests stratified by treatment group. Cumulative days at clinical and patient-reported responses were compared by ancova. The trial was registered with ClinicalTrials.gov (NCT03573323).

RESULTS

Of the 1027 patients randomly assigned, 90% completed the trial (465 of 520 ixekizumab and 459 of 507 guselkumab). As early as week 2 and through week 16, more patients on ixekizumab achieved PASI 100 (P < 0·01). At week 24, ixekizumab was noninferior to guselkumab (50% vs. 52%, difference -2·3%), with no statistically significant difference in PASI 100 (P = 0·41). More patients receiving ixekizumab showed completely clear nails at week 24 (52% vs. 31%, P = 0·007). The median time to first PASI 50/75/90 and PASI 100 were 2 and 7·5 weeks shorter, respectively, for patients on ixekizumab vs. guselkumab (P < 0·001). Patients on ixekizumab also had a greater cumulative benefit, with more days at PASI 90 and 100, with Dermatology Life Quality Index of 0 or 1, and itch free (P < 0·05). The frequency of serious adverse events was 3% for each group, with no new safety signals.

CONCLUSIONS

Ixekizumab was noninferior to guselkumab in complete skin clearance and superior in clearing nails at week 24. Ixekizumab cleared skin more rapidly in patients with moderate-to-severe plaque psoriasis, with a greater cumulative benefit, than guselkumab. Overall, the safety findings were consistent with the known safety profile for ixekizumab.

Links

PMC Free PDF

Authors+Show Affiliations

Blauvelt A

Oregon Medical Research Center, Portland, OR, USA.

Leonardi C

Central Dermatology, St Louis, MO, USA.

Elewski B

Deparment of Dermatology, University of Alabama, Birmingham, AL, USA.

Crowley JJ

Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, CA, USA.

Guenther LC

Guenther Research Inc, London, ON, Canada.

Gooderham M

SKiN Centre for Dermatology, Peterborough, ON, Canada.

Langley RG

Dalhousie University, Halifax, NS, Canada.

Vender R

Dermatrials Research Inc, Hamilton, ON, Canada.

Pinter A

Clinic for Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt am Main, Germany.

Griffiths CEM

Dermatology Centre, Salford Royal Hospital, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, UK.

Tada Y

Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.

Elmaraghy H